Shots: The companies have expanded their clinical trial collaboration and supply agreement for IDE196 and crizotinib. The study will evaluate combination therapy in patients with solid tumors having GNAQ or GNA11 mutations (GNAQ/11), including MUM, skin melanoma, lung cancer, and colorectal cancer The two global companies have established JDC and there will be joint decision […]Read More
Shots: The P-II Spotlight 203 study will evaluate the combination of BO-112 (intra-tumoral administration) + Keytruda (pembrolizumab) with CR or PR as its 1EPs. The study will evaluate disease control rates, DoR, PFS, OS, as well as safety, tolerability, and PK of the therapy in ~40 patients The collaboration will focus on the evaluation of […]Read More
Shots: The two companies will work together to research, discover, and develop therapeutic options related to the deficiency of the protein GBA which is a gene linked to Gaucher disease The collaboration will combine Evotec’s iPSC platform and drug discovery and development capabilities with Centogene’s global rare disease platform, including iPSC lines The collaboration follows […]Read More
Shots: Eli Lilly initiates P-III BLAZE-2 study assessing LY-CoV555 to prevent SARS-CoV-2 infection and COVID-19 in residents and staff at long-term care facilities in the US (skilled nursing facilities, commonly referred to as nursing homes, and assisted living facilities) The company will enroll up to ~2400 patients and test whether a single dose of LY-CoV555 […]Read More
Shots: The real-world evidence partnership will allow the Roche to access PicnicHealth’s set of de-identified patient records to gain insights on certain diseases and treatments The collaboration will initially focus on MS and may be extended to support Huntington’s disease (HD), paroxysmal nocturnal hemoglobinuria (PNH), and hemophilia The companies signed a multi-year collaboration that combines […]Read More
Shots: F-star to receive option exercise payment and will be eligible to get milestones and royalties on net sales of therapies resulting from the collaboration. Merck KGaA exercises its option to license a preclinical program in its existing agreement with F-star Merck KGaA will be responsible for the development and commercialization of the preclinical program […]Read More
Shots: The companies extend their existing collaboration to evaluate Immunomedics’ Trodelvy (sacituzumab govitecan-hziy) in combination with Tecentriq (atezolizumab) in patients with mUC and mNSCLC. The partners have ongoing collaboration in 1L metastatic triple-negative BC Roche will conduct two P-Ib/II studies utilizing MORPHEUS platform. The MORPHEUS-mUC study will evaluate Tecentriq + Trodelvy vs Tecentriq as monothx. […]Read More
Shots: Ascentage will be responsible to sponsor the P-Ib/II trial (NCT03611868) which involves assessing of APG-115 in combination with Keytruda, to evaluate its safety and efficacy in solid tumors (i,e., NSCLC, melanoma, Urothelial cancer, Liposarcoma, MPNST and ATM mutated/p53 WT tumors resistant or relapsed to PD-1/PD-L1 treatment or without previous PD-1/PD-L1 treatment) The companies will […]Read More
Shots: Translate Bio to receive $425M up front consisting $300M in cash and $125M as equity investment at $25.59/ share representing a 50% premium to the 20-day moving average share price prior to signing. The company will receive ~$1.9B as milestones, including $450M milestones under the 2018 agreement and expects $360M in next few years […]Read More
Shots: AbbVie collaborated with Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center (EMC) to develop a novel Ab to prevent and treat COVID-19. The collaboration focuses on advancing 47D11, discovered by UU, EMC and HBM that targets the domain of the spike protein of SARS-CoV-2 AbbVie will support UU, EMC, and HBM in […]Read More
Copyright ©2020 PharmaShots | Powered by Octavus Consulting
